BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, March 27, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Nov. 25, 2003
View Archived Issues
ANUP peptides reduce tumor growth and inhibit angiogenesis
Read More
R&D highlights from the Rodman & Renshaw Techvest Healthcare Conference: Callisto
Read More
Medivir and Hengrui to develop protease inhibitor drugs for COPD
Read More
Xantryl advances for psoriasis
Read More
Tolerance of MEDI-522 in patients with advanced solid tumors
Read More
Synergistic antitumor effects described for CNTO-95 and paclitaxel
Read More
Trabectedin alone or in combination in the treatment of advanced solid tumors
Read More
Increased antitumor activity of pertuzumab combined with cytotoxic drugs in NSCLC models
Read More
Metastatic melanoma as a potential new indication for arsenic trioxide
Read More
Enzon enters collaborative development program with NIH for SS1P
Read More
PPD and Syrrx to develop orally delivered DP4 inhibitors
Read More
Therion evaluates Prostvac-VF in new phase II prostate cancer study
Read More
R&D highlights from the Rodman & Renshaw Techvest Healthcare Conference: Introgen Therapeutics
Read More
R&D highlights from the Rodman & Renshaw Techvest Healthcare Conference: Cortex
Read More
Oritavancin NDA filing delayed
Read More
Lilly Icos receives FDA approval for Cialis
Read More
Phase II MEND-CABG study cleared to commence in U.S. and Canada
Read More
Merck & Co. discontinues phase III program for MK-767
Read More
Phase I study of oral methylnaltrexone commences dosing
Read More
Zeria presents novel gastric antisecretory agents in a recent patent
Read More
New opioid analgesics prepared and tested by Nippon Chemiphar team
Read More
New muscarinic M3 antagonists and their use in urinary incontinence, COPD, IBS, etc.
Read More
Merck researchers identify new CB1 modulators for obesity and other uses
Read More
New FTase inhibitors in early development at Janssen
Read More
Antioxidants and their therapeutic use covered by Tanabe Seiyaku patent
Read More
Shionogi describes GM-CSF-like compounds with potential in cancer and neutropenia
Read More
Boehringer Ingelheim presents new muscarinic M3 antagonists
Read More
Antitumor activity of MLN-944 due to inhibition of DNA and RNA synthesis
Read More
New hypoxic cytotoxin shows promising in vitro and in vivo activity
Read More
